No Data
The market is booming as Johnson, an innovative drug company, sees a 13% increase in performance | Jiann zhiyan Research
The market should not lose confidence in China's innovative drugs.
Annual Financial Report
Hengrui received an FDA warning letter | Jianzhi Research
A problem that should not have been present arose from a leader. Following the June FORM483 incident, Hengrui has one more opportunity to rectify the issue.
Silence Therapeutics To Receive $2M Research Milestone Payment From Hansoh Pharma, Following The Achievement Of A Second Undisclosed Milestone Related To The First Target Under The Collaboration
Hengrui's FORM 483 is not that simple | Jianzhi Research
According to the FDA website, Hengrui's January on-site inspection has entered the OAI phase, which means that the FDA is not satisfied with the company's first-stage response and corrective actions, and has made a formal regulatory decision. However, it should be emphasized that Hengrui still has the opportunity to submit rectification measures before further regulatory measures are taken. And this on-site inspection has nothing to do with the dual AI therapy going global.
Summit Therapeutics Falls Almost 20% as it Returns Part of Last Week's 280%+ Rally